Remove Heart Failure Remove Quality of Life Remove Technology
article thumbnail

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

DAIC

mtaschetta-millane Thu, 07/11/2024 - 10:53 July 11, 2024 — Heart Test Laboratories, Inc. Heart failure (HF) is a growing worldwide public health issue affecting 64 million people annually 1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.

article thumbnail

Effects of exercise-based cardiac rehabilitation delivery modes on exercise capacity and health-related quality of life in heart failure: a systematic review and network meta-analysis

Open Heart

Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.

article thumbnail

FDA Expands Indication for Impella Heart Pumps for Pediatric Patients

DAIC

12, 2024 Physicians have a new treatment option for many of the sickest pediatric patients with heart failure andcardiogenic shock. and Impella CP enable heart recovery as part of the world's smallest heart pump platform. with SmartAssist tim.hodson Wed, 12/18/2024 - 14:06 Dec.

article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

"Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,

Tricuspid 102
article thumbnail

What is new in Heart failure management ? Ultrasonic cardiac re-synchronization : The WiSE -CRT device

Dr. S. Venkatesan MD

We now have one more technology, on the verge of approval by the FDA. Final message WiSE CRT uses some revolutionary technology and it is a welcome addition in few eligible patients. However, advanced heart failure therapy never means it can be achieved only by state-of-the-art technology. Reference 1. 2024.2050 2.

article thumbnail

Cardiac Dimensions Appoints Satya Shreenivas, MD, as Chief Medical Officer

DAIC

There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies. Dr. Shreenivas is a frequent speaker at major scientific meetings and has been widely published in peer-reviewed journals across the structural heart, heart failure, and coronary arenas.

article thumbnail

Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial

DAIC

Geisinger is at the forefront of research and technological advancements that allow for better patient outcomes and improvements in their quality of life.” Cardiac amyloidosis is caused by protein buildup between the muscle cells of the heart, increasing the thickness of the heart.